Daptomycin and Hematologic Effects
Daptomycin does not typically cause clinically significant decreases in white blood cell count, but rare cases of thrombocytopenia and neutropenia have been reported, particularly with prolonged use. 1
Primary Hematologic Adverse Effects
According to FDA labeling, the recognized hematologic effects of daptomycin occurring in <1% of patients include 1:
- Thrombocytopenia (low platelet count)
- Leukocytosis (elevated WBC - more common than leukopenia)
- Thrombocytosis (elevated platelet count)
- Eosinophilia (elevated eosinophils)
Notably, leukocytosis is actually listed as an adverse effect rather than leukopenia, suggesting daptomycin is more likely to raise WBC than lower it in typical clinical use.
Rare but Documented Cases
While not a common adverse effect, case reports document simultaneous thrombocytopenia and neutropenia with prolonged daptomycin therapy 2. A 2016 case report described culture-negative endocarditis treated with extended daptomycin course resulting in both low platelets and low neutrophils. However, this remains exceptional rather than typical.
Clinical Context: Use in Neutropenic Patients
Importantly, daptomycin has been successfully used in neutropenic patients without worsening their neutropenia. A multicenter registry study of 186 neutropenic patients (≤500 cells/mm³) with documented gram-positive infections showed 85% success rates, with no difference in outcomes between patients with WBC ≤100 versus 101-499 cells/mm³ 3. Only 6% experienced possibly related adverse events, and the degree of neutropenia did not affect treatment success.
Monitoring Recommendations
Based on FDA guidelines and clinical practice 1:
- Weekly CPK monitoring is the primary laboratory surveillance required (for myopathy/rhabdomyolysis risk)
- Routine CBC monitoring is not specifically mandated by FDA labeling for daptomycin
- If prolonged therapy (>2 weeks) is planned, consider baseline and periodic CBC monitoring as general practice, though not evidence-mandated
Key Clinical Pitfalls
- Do not confuse daptomycin with linezolid: Linezolid causes significant hematologic toxicity with thrombocytopenia, anemia, and neutropenia, particularly with prolonged use 4. This is reversible but common with linezolid, not daptomycin.
- Eosinophilia may signal eosinophilic pneumonia: If eosinophils rise significantly, evaluate for pulmonary symptoms as daptomycin-induced eosinophilic pneumonia is a recognized serious adverse effect 4.
Bottom Line
Daptomycin does not routinely drop WBC or significantly affect complete blood counts in the vast majority of patients. When hematologic changes occur, they are rare, typically involve thrombocytopenia rather than leukopenia, and are associated with prolonged therapy. The drug can be safely used even in severely neutropenic patients without worsening their neutropenia.